Capricor Therapeutics (NASDAQ:CAPR) Shares Gap Up on Strong Earnings

Capricor Therapeutics Inc (NASDAQ:CAPR)’s share price gapped up prior to trading on Thursday following a stronger than expected earnings report. The stock had previously closed at $12.22, but opened at $12.56. Capricor Therapeutics shares last traded at $13.79, with a volume of 401,510 shares.

The biotechnology company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.15. Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%. The firm had revenue of $11.13 million during the quarter, compared to analyst estimates of $9.87 million.

Analyst Ratings Changes

CAPR has been the subject of several recent research reports. Cantor Fitzgerald reissued an “overweight” rating and set a $30.00 price objective on shares of Capricor Therapeutics in a research report on Thursday. HC Wainwright reissued a “buy” rating and set a $77.00 price objective on shares of Capricor Therapeutics in a research report on Monday, March 17th. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $34.50.

Institutional Investors Weigh In On Capricor Therapeutics

A number of large investors have recently made changes to their positions in the company. Vanguard Group Inc. lifted its position in shares of Capricor Therapeutics by 44.4% during the 4th quarter. Vanguard Group Inc. now owns 2,276,784 shares of the biotechnology company’s stock valued at $31,420,000 after buying an additional 700,243 shares in the last quarter. Farallon Capital Management LLC purchased a new position in shares of Capricor Therapeutics during the 4th quarter valued at about $31,056,000. Geode Capital Management LLC lifted its holdings in Capricor Therapeutics by 37.8% in the 4th quarter. Geode Capital Management LLC now owns 879,468 shares of the biotechnology company’s stock worth $12,139,000 after purchasing an additional 241,279 shares in the last quarter. Altium Capital Management LLC lifted its holdings in Capricor Therapeutics by 150.5% in the 4th quarter. Altium Capital Management LLC now owns 714,000 shares of the biotechnology company’s stock worth $9,853,000 after purchasing an additional 429,000 shares in the last quarter. Finally, Woodline Partners LP purchased a new position in Capricor Therapeutics in the 4th quarter worth approximately $8,693,000. 21.68% of the stock is currently owned by institutional investors.

Capricor Therapeutics Stock Performance

The stock has a fifty day moving average of $14.06 and a 200 day moving average of $14.55. The company has a market capitalization of $584.74 million, a PE ratio of -12.13 and a beta of 4.10.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.